• Email:sales@AmericanPharmaWholesale.com
  • Site Map




Please email us at Sales@AmericanPharmaWholesale.com with our item No, NDC#, UPC# or best is product link. We are located in Oceanside, California. Search over 100,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name.


Menu

FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx

iTEM NO Rx3687456 3687456  NDC No. 19515-0906-52 19515-906-52 1951590652 19515090652  UPC/GTIN No. 3-19515-90652-4 319515-906524 319515906524 MPN 90652FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline RxThis Item Can Only Be Ordered By A Drug Mfg, Wholesaler,Pharmacy,Physician, Dentist, Podiatrist, Optometrist,Veterinarian,Naturopath,Licensed Lab, Physical Therapist & Pharmacist(scope).FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline RxFLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx

FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx

$200.34$189.99

RX ITEM-FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline. iTEM NO Rx3687456 3687456 NDC No. 19515-0906-52 19515-906-52 1951590652 19515090652 UPC/GTIN No. 3-19515-90652-4 319515-906524 319515906524 MPN 90652 Only Physician,Pharmacy or Licensed Facility can order this RX ITEM.

Have a question?

FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx
These highlights do not include all the information needed to use FLULAVAL QUADRIVALENT safely and effectively. See full prescribing information for FLULAVAL QUADRIVALENT.

FLULAVAL QUADRIVALENT (Influenza Vaccine) injectable suspension, for intramuscular use
2019-2020 Formula
Initial U.S. Approval: 2013

INDICATIONS AND USAGE
FLULAVAL QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLULAVAL QUADRIVALENT is approved for use in persons aged 6 months and older. (1)
DOSAGE AND ADMINISTRATION
For intramuscular injection only. (2)



a One dose or 2 doses (0.5�'mL each) depending on vaccination history as per the annual Advisory Committee on Immunization Practices (ACIP) recommendation on prevention and control of influenza with vaccines. If 2 doses, administer each 0.5�'mL dose at least 4 weeks apart. (2.1)
Age
Vaccination Status
Dose and Schedule
6 months through 8 years
Not previously vaccinated with influenza vaccine
Two doses (0.5�'mL each) at least 4 weeks apart (2.1)
Vaccinated with influenza vaccine in a previous season
One or 2 dosesa (0.5�'mL each) (2.1)
9 years and older
Not applicable
One 0.5�'mL dose (2.1)


DOSAGE FORMS AND STRENGTHS
Suspension for injection:

0.5-mL single-dose prefilled syringes ( 3)

5-mL multi-dose vials containing 10 doses (each dose is 0.5 mL). ( 3)
CONTRAINDICATIONS
History of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine. (4, 11)
WARNINGS AND PRECAUTIONS

If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks. ( 5.1)

Syncope (fainting) can occur in association with administration of injectable vaccines, including FLULAVAL QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope. ( 5.2)






ADVERSE REACTIONS

In adults, the most common (≥10%) solicited local adverse reaction was pain (60%); most common solicited systemic adverse events were muscle aches (26%), headache (22%), fatigue (22%), and arthralgia (15%). ( 6.1)

In children aged 6 through 35 months, the most common (≥10%) solicited local adverse reaction was pain (40%); most common solicited systemic adverse events were irritability (49%), drowsiness (37%), and loss of appetite (29%). ( 6.1)

In children aged 3 through 17 years, the most common (≥10%) solicited local adverse reaction was pain (65%). ( 6.1)

In children aged 3 through 4 years, the most common (≥10%) solicited systemic adverse events were irritability (26%), drowsiness (21%), and loss of appetite (17%). ( 6.1)

In children aged 5 through 17 years, the most common (≥10%) solicited systemic adverse events were muscle aches (29%), fatigue (22%), headache (22%), arthralgia (13%), and gastrointestinal symptoms (10%). ( 6.1)
To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.






USE IN SPECIFIC POPULATIONS
Geriatric Use: Antibody responses were lower in geriatric subjects who received FLULAVAL QUADRIVALENT than in younger subjects. (8.5)













See 17 for PATIENT COUNSELING INFORMATION.
Revised: 7/2019

iTEM NO Rx3687456 3687456  NDC No. 19515-0906-52 19515-906-52 1951590652 19515090652  UPC/GTIN No. 3-19515-90652-4 319515-906524 319515906524 MPN 90652
FLULAVAL QUAD SY10X0.5ML 2019-
iTEM NO Rx3687456 3687456 NDC No. 19515-0906-52 19515-906-52 1951590652 19515090652 UPC/GTIN No. 3-19515-90652-4 319515-906524 319515906524 MPN 90652

FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx
FLULAVAL QUAD SY10X0.5ML 2019-
FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx

This Item Can Only Be Ordered By A Drug Mfg, Wholesaler,Pharmacy,Physician, Dentist, Podiatrist, Optometrist,Veterinarian,Naturopath,Licensed Lab, Physical Therapist & Pharmacist(scope).
FLU VACC QS 2014-15(36MOS
This Item Can Only Be Ordered By A Drug Mfg, Wholesaler,Pharmacy,Physician, Dentist, Podiatrist, Optometrist,Veterinarian,Naturopath,Licensed Lab, Physical Therapist & Pharmacist(scope).

FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx
Glaxosmithkline/Rx
FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx

FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx
FLULAVAL QUAD SY10X0.5ML 2019-
FLULAVAL QUAD SY10X0.5ML 2019-20 PF by Glaxosmithkline Rx